Disc Medicine Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
2.5%projected annual EPS growth
Analyst Coverage
12analysts covering
FY EPS (est.)
-$6.67next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Phase 3 APOLLO Topline Data Readout | 31 Dec 2026 |
| DISC-3405 PV and SCD Initial Data Readout | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly730.2MTarget: Sufficient to fund operations into 2029
Phase 3 APOLLO Trial Enrollment Quarterly183.0Target: 183 (Completed)
RALLY-MF Phase 2 Trial Enrollment Quarterly61.0Target: 61 (Completed)
Watch Items
- Topline data readout from the Phase 3 APOLLO trial of bitopertin in EPPTrigger: Q4 2026Action: Evaluate clinical efficacy (sunlight exposure outcomes) and safety to prepare for traditional FDA approval resubmission.
- FDA traditional approval decision for bitopertin in EPPTrigger: Mid-2027Action: Monitor regulatory response following the planned CRL response submission post-APOLLO data.
- Initial clinical data from DISC-3405 in Polycythemia Vera (PV) and Sickle Cell Disease (SCD)Trigger: Q4 2026Action: Assess proof-of-concept safety and pharmacodynamics to validate the broader iron homeostasis platform.
Research as of 19 Jun 2026